ArticleInfectious diseases of poverty2025
Effects of Wolbachia removal on microbial composition and diversity in Aedes albopictus: implication of using wAlbB for discriminating irradiation-based sterile and wild males.
Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe sterile insect technique (SIT) requires distinguishing sterile from wild male mosquitoes to evaluate male qualities and maintain an appropriate release ratio for efficient population suppression. Current dye/powder marking methods have limitations and may affect SIT effectiveness, necessitating alternative discrimination strategies. Aedes albopictus naturally harbors two Wolbachia infections (wAlbA/wAlbB), which can be eliminated via tetracycline. Although Wolbachia removal minimally affect host fitness, its impact on microbiota remains unclear. Characterizing post-elimination microbial communities is the first step to identify novel endogenous biomarkers for SIT monitoring.
methodsWe analyzed the bacterial diversity and composition of two strains of wild-type GUA (Wolbachia-infected) and GT (Wolbachia-free) mosquitoes using the 16S rRNA V3-V4 region sequencing. qPCR was employed to confirm the relative abundance of four major bacterial genera, while PCR was used to validate selected biomarkers for distinguishing factory-reared sterile males from wild males. Kruskal-Wallis or Mann-Whitney test was used to analyze the comparable parameters between GUA and GT strains.
resultsFive-day-old GUA and GT females showed similar microbial diversity/composition, while young males shared diversity but differed in composition. The core microbiota in both strains consisted of Proteobacteria (64.27%), Firmicutes (16.09%), Actinobacteriota (11.22%), and Bacteroidota (4.96%). Asaia was dominant in both strains (GUA: 47.33%; GT: 32.69%), whereas Enterococcus increased in GT males with aging. Wolbachia was absent in GT mosquitoes, and Elizabethkingia was undetected in GUA males. qPCR further confirmed these trends. PCR analysis revealed that wAlbB exhibited higher stability in differentiating factory-reared GT males from their wild counterparts (96.7% infection in field males, n = 60) compared to wAlbA (61.7%, n = 60) or Enterococcus (65.8%, n = 120). The mark-release-recapture experiment further confirmed the detectability using wAlbB biomarker.
conclusionsWithout obvious fitness costs observed previously in the Ae. albopictus GT strain compared to GUA strain, the removal of Wolbachia significantly changes the microbial composition in male mosquitoes in this study. Wolbachia wAlbB is recommended as a reliable biomarker for distinguishing sterile males from wild males when using GT strain in SIT programs targeting Ae. albopictus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.